Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009 he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| foaf:name |
|
| foaf:depiction | |
| dc:description |
|
| alma mater | |
| award | |
| birth date |
|
| birth year |
|
| known for | |
| thumbnail |